The aim of the study was to characterize contemporary patterns and correlates of testosterone therapy (TTh) use and discontinuation by HIV serostatus among men in the Multicenter AIDS Cohort Study (MACS).
Introduction
The rising use of testosterone therapy (TTh) in the USA over the past decade [1] [2] [3] has elicited concerns regarding both the appropriateness of its use and uncertainty over its benefits and risks. The recent set of seven randomized placebo-controlled Testosterone Trials (TTrials) demonstrated several potential benefits among older men, including benefits for bone density, sexual desire and function, mood, and depressive symptoms [4, 5] . However, the association of TTh with cardiovascular outcomes remains inconclusive [6] . The US Food and Drug Administration (FDA) released a safety communication for testosterone products in January 2014 [7, 8] , following the publication of two studies that reported elevated risks of heart attack and stroke associated with TTh use [9] [10] [11] . Yet other studies have not confirmed these findings [12] [13] [14] [15] , and new data continue to conflict. For example, in one of the TTrials, TTh was associated with a higher risk of coronary artery noncalcified plaque progression in [16] , while a large observational study published the same month found that TTh use was associated with a lower risk of cardiovascular events [17] .
The ongoing uncertainty over potential cardiovascular risks associated with TTh is salient for HIV-infected men, who have an elevated burden of cardiovascular disease (CVD) [18, 19] and may be more likely to have an indication for TTh use. Testosterone was often prescribed for AIDS-related wasting prior to the availability of effective combination antiretroviral therapy (cART), and HIVrelated wasting is an indication for short-term testosterone use in the Endocrine Society Guidelines [20] . Moreover, hypogonadism has been found to be prevalent among men with HIV infection [21] [22] [23] [24] [25] , and agingrelated testosterone decline will further contribute to hypogonadism as the HIV-infected population ages [26] .
Despite these linkages, epidemiological and clinical data regarding TTh use among men with HIV infection are limited. To the best of our knowledge, there is only one published estimate of TTh use among HIV-infected men in the cART era, documenting a TTh initiation rate of 19.7/1000 person-years from 1996 to 2011 [27] , more than twice the rate reported in a commercially insured US population in 2011 [1] . Without an HIV-uninfected control group, the investigators were unable to examine differences between testosterone users with and without HIV infection. Furthermore, the rates and predictors of TTh discontinuation among men with HIV infection have not been described, and it is unknown whether they are represented by rates reported for overall populations of TTh users. We sought to characterize contemporary patterns and correlates of TTh use and discontinuation by HIV serostatus among men in the Multicenter AIDS Cohort Study (MACS) from 2012 to 2015. We also compared the cardiovascular risk profiles among TTh users with and without HIV infection and evaluated whether the rate of discontinuation increased after the public release of the FDA safety communication on testosterone products.
Methods

Study population
The MACS is a prospective cohort study of HIV infection among men who have sex with men (MSM). Since 1984, a total of 7343 HIV-infected and HIV-uninfected men were enrolled in four sites: Baltimore/Washington DC, Chicago, Pittsburgh, and Los Angeles. Details of the design and methods have been published [28, 29] ; briefly, men attend semi-annual study visits that include structured questionnaires, physical examination, and the collection of blood samples (forms available: www.aidsc ohortstudy.org/researchers). The primary analyses of TTh use included data from the 2400 (1286 HIV-positive and 1114 HIV-negative) participants under active follow-up from 2012 to 2015. Study procedures were approved by Institutional Review Boards at each site and all participants provided informed consent.
Outcome and exposure variables
Self-reported testosterone use data were obtained through an interviewer-administered questionnaire. HIV serostatus was determined using an enzyme-linked immunosorbent assay (ELISA) and confirmed using Western blot. AIDS was confirmed through medical records and cART use was assessed using structured questionnaires; we dichotomized the time period of cART initiation using the year 2000, before which TTh was commonly prescribed in conjunction with cART for HIV-infected men with hypogonadism and wasting [30] . Participants self-reported date of birth, race, education, health insurance coverage, use of medications including erectile dysfunction drugs, number of sexual partners, smoking, recreational drug use, and alcohol use in the preceding 6 months. Recreational drug use was categorized as no drug use, use of marijuana only, or use of at least one of the following substances: inhaled nitrates, cocaine or crack, opiates, uppers, downers, phencyclidine, and gamma-hydroxybutyric acid. Body mass index (BMI) was measured using weight and height (kg/m 2 ), and classified as low (< 20.5), normal (20.5-24.9) , overweight (25-29.9 ) and obese (≥ 30). The frailty phenotype was defined as the simultaneous presence of at least three of the following five components: (1) weakness (determined by grip strength), (2) slowness (determined by a timed walk), (3) selfreported unintentional weight loss ≥ 10 pounds, (4) selfreported exhaustion, and (5) self-reported limitation in physical activity; men with one or two components were classified as pre-frail [31, 32] . The American Heart Association/American College of Cardiology (AHA/ACC) 10-year CVD risk score was calculated, and categorized as low, moderate and high risk using established cutpoints [33] .
Statistical analysis
TTh prevalence and correlates Testosterone therapy prevalence at the most recent study visit was stratified by HIV serostatus and age. The overall prevalence by HIV serostatus was age-adjusted using direct standardization, using the age distribution of the total cohort as that of the standard population. We compared the reasons for TTh use, mode of administration, and prescription status by HIV serostatus using v 2 tests.
We evaluated the following correlates: demographic (age, race, study site and college education), behavioural (sexual partners in the past 6 months, alcohol use, recreational drug use and smoking status), and health-related (HIV serostatus, BMI, frailty phenotype, CVD risk category and erectile dysfunction medication use) factors. After carrying forward values from 2011, missing values for specific covariates ranged from 0.3% for cholesterol medication use to 26% for CVD risk category (as a consequence of missing fasting glucose, cholesterol or blood pressure measurements among men who did not complete a full study visit or participated by phone). Missing data were addressed using multiple imputation iterative chained equations (10 data sets). We estimated prevalence ratios (PRs) for TTh use using Poisson regression models with robust variance on multiple imputation data sets. All demographic factors and other factors that correlated with TTh in unadjusted models (P-value < 0.15) were included in multivariable analyses. We repeated the analysis stratified by HIV serostatus to evaluate whether the correlates of TTh differed by HIV serostatus.
TTh discontinuation
The analytical sample for the longitudinal analysis of TTh discontinuation included participants who used TTh at a visit and completed at least one subsequent study visit during 2012-2015. Multiple visits per participant were included; visits were censored after discontinuation or the participant's last visit up to 2015. The discontinuation date was defined as the midpoint between the last visit date at which TTh use was reported and the first subsequent visit when use was not reported. An indicator variable determined whether the visit occurred after 31 January 2014, the date of the first FDA safety communication on testosterone. We carried an individual's values forward and backward from before and after the visit with the missing covariate, respectively (missing data ranged from < 1% for behavioural variables to 15% for BMI). We used multiple imputation with iterative chained equations to impute missing baseline values (10 data sets). Imputed values were carried forward for subsequent visits. We assessed the incidence rate ratios for discontinuation using multiple imputation estimates and multivariable Poisson regression models accounting for multiple observations per individual. Predictors were assessed at the most recent visit at which TTh use was reported and included the previously defined covariates and testosterone mode (transdermal vs. injection). The multivariable model included demographics, whether the time was pre/post the FDA safety communication, and CVD risk category; remaining health and behavioural covariates were included if P < 0.15 for the unadjusted association with TTh discontinuation. We evaluated whether the association between the FDA warning and discontinuation was modified by HIV serostatus or CVD risk score category. Statistical significance was determined by a two-sided P-value < 0.05. Analyses used Stata 13.1 (StataCorp, College Station, TX, USA).
Results
Characteristics of the study population are shown in Table 1 . HIV-infected men were younger, less likely to be white, and less likely to have a college degree compared with HIV-uninfected men. Overall, 94% of men had health insurance coverage, without a difference by HIV serostatus. HIV-infected men had lower BMI and were less likely to be in the 10-year CVD high-risk category than HIV-uninfected men (53.4% vs. 64.4%, respectively), but were more likely to be current smokers (26.3% vs. 17.6%, respectively). Among the HIV-infected men, 88.7% were currently on cART, with a median CD4 T-cell count of 641 cells/lL [interquartile range (IQR) 466, 841 cells/lL] and 83.3% had plasma HIV RNA levels below the limit of detection (50 HIV-1 RNA copies/mL); 55% of the men started cART before 2000, and 12.2% had a history of clinical AIDS.
Prevalence of and reasons for testosterone use
More HIV-infected men reported TTh use compared with the HIV-uninfected men in all age strata, with an overall age-standardized prevalence of 17% [95% confidence interval (CI) 14.9, 19.2%] vs. 5% (95% CI: 4.1, 6.6%), respectively ( Fig. 1) . The prevalence of testosterone use increased with age among HIV-infected men, ranging from 5% of men aged < 50 years to 17.2% among men aged 50-59 years, and 25% of among men aged ≥ 60 years.
Nearly all TTh users reported receiving a prescription from a health care provider (99%). Transdermal TTh (gels or patches) was the most popular formulation, used by 69% of men, followed by injection (27%). Low serum Values are percentages, unless otherwise specified. AHA/ACC, American Heart Association/American College of Cardiology; ART, antiretroviral therapy; BMI, body mass index; cART, combination antiretroviral therapy; CVD, cardiovascular disease; IQR, interquartile range. *Self-report of any medical coverage, public or private, since last semi-annual MACS visit. † BMI was calculated as weight in kilograms divided by height in metres squared. ‡ Pre-frailty includes one or two and the frailty phenotype includes three or more of the following five components: (1) weakness (determined by grip strength), (2) slowness (determined by timed walk), (3) self-reported unintentional weight loss of 10 pounds or more, (4) self-reported exhaustion, and (5) self-reported limitation in physical activity. §
The AHA/ACC pooled cohort equation includes age, race, systolic blood pressure, hypertension treatment, smoking status and diabetes. Total and high-density lipoprotein (HDL) cholesterol were measured in blood samples.
testosterone level was the most common reason for TTh use (90%). Other reasons included the desire for more strength or energy (37%), fatigue (36%), low libido (29%), and erectile dysfunction (16%). Among men taking TTh, those with HIV infection were half as likely to concurrently take medication for erectile dysfunction as HIVuninfected men (10% vs. 20.2%, respectively; P = 0.02). Only 8% of men reported using TTh to improve athletic performance. HIV-infected men were significantly more likely than HIV-uninfected men to report using TTh to build muscle (32.1% vs. 6.5%, respectively; P < 0.001) and combat wasting (15.3% vs. 1.6%, respectively; P < 0.01). Among the 30 HIV-infected men who used TTh to combat wasting, 97% had initiated cART prior to 2000, and 36% had a history of clinical AIDS. Among the 63 HIV-infected men who used TTh to build muscle, 84% began cART prior to 2000 and 27% had an AIDS diagnosis.
Correlates of testosterone use
After adjusting for demographic and behavioural factors, HIV-infected men were > 3 times as likely to use testosterone as HIV-uninfected men [adjusted prevalence ratio (aPR) 3.71; 95% CI: 2.79, 4.92; Table S1 ). Additionally, the inverse association observed between TTh use and current smoking was stronger among HIV-uninfected men (P for interaction = 0.07).
Testosterone discontinuation
Overall, 316 TTh users contributed 556 person-years of follow-up from 2012 to 2015; 71% were HIV-infected (Table 3 ). The median ages were 55.8 and 60.9 years for HIV-infected and uninfected men, respectively. Approximately 70% of the testosterone users were in the highest CVD risk category, with no difference by HIV serostatus; the median 10-year risk score was 9% and 11.6% for HIV-infected and HIV-uninfected men, respectively. Dyslipidaemia was highly prevalent among TTh users, irrespective of HIV serostatus, as were hypertension and diabetes. Compared with HIV-uninfected TTh users, HIVinfected men had a higher prevalence of smoking and a lower prevalence of obesity (see Table S2 for levels of these characteristics among TTh nonusers). Among TTh users, 116 discontinued use, yielding a discontinuation rate of 20.9 per 100 person-years (95% CI: 17.4, 25.0 per 100 person-years). The rate of discontinuation was significantly lower among HIV-infected men ( Fig. 1 Testosterone therapy use prevalence, by HIV serostatus and age category. Total prevalence is age-standardized using the age distribution of the total study population. The denominators for each age-serostatus category from left to right were 463 for HIV-positive men aged < 50 years; 210 for HIV-negative men aged < 50 years; 482 for HIV-positive men aged 50-59 years; 356 for HIV-negative men aged 50-59 years; 341 for HIV-positive men aged ≥ 60 years; and 548 for HIV-negative men aged ≥ 60 years.
demographic, health and behavioural characteristics, with discontinuation less likely among HIV-infected men compared with HIV-uninfected men [adjusted incidence ratio (aIR) 0.44; 95% CI: 0.29, 0.65] ( Table 4) . After adjusting for covariates, discontinuation was 40% higher after the release of the FDA safety communication regarding 
Discussion
In this large, well-characterized and prospectively followed cohort, HIV-infected men were more than three times as likely to use TTh and half as likely to discontinue TTh compared with uninfected men, independent of relevant co-factors. Testosterone utilization was highest in the oldest age group, with 1 in 4 HIV-infected men ≥ 60 years old using TTh. Our findings are consistent with the high TTh initiation rates reported in the few existing studies among HIV-infected men [27, 34] , and are enhanced by the comparison group of uninfected men which enabled us to quantify the difference in TTh use between HIV-infected and uninfected men. To our knowledge, this is the first study to document a significantly lower rate of TTh discontinuation among HIV-infected men.
Despite the markedly higher TTh use among men with HIV infection, many of the self-reported reasons for use were similar for HIV-infected and uninfected men. Low testosterone levels were the main reasons cited for TTh use regardless of HIV serostatus, cited by 90% of men, and in this population, symptoms regarding energy and fatigue were more common than those related to sexual dysfunction. Athletic performance was reported as a reason for TTh by just 8% of men, although physical performance motivations could contribute to other response categories, such as strength and energy or building muscle. However, HIV-infected men were significantly more likely than uninfected men to use TTh to combat weight loss and build muscle. We hypothesized that HIV-infected men using TTh for these reasons were more likely to have a history of AIDS-related weight loss, and this was supported by the finding that the prevalence of AIDS among these men was 36% and 27%, respectively, more than two times the level in the total sample of HIV-infected men (12%). The 2010 Endocrine Society guidelines recommend the consideration of short-course testosterone therapy for HIV-infected men with low testosterone levels and weight loss [20] , based on evidence from studies conducted in the 1990s and early 2000s, when significant HIV-related weight loss and delays in initiation of effective HIV treatment were more common. Although the prevalence of HIV wasting has decreased dramatically since potent cART regimens became available, our findings may suggest that men who were infected early in the HIV epidemic continue to be concerned about the effects of HIV infection on muscle mass and perceive that TTh may have a role in muscle mass preservation as they age. This may contribute to the higher prevalence of use and lower discontinuation rate observed among HIVinfected compared with uninfected men. We identified several factors associated with TTh use and discontinuation that were salient for both HIVinfected and uninfected men. TTh use, but not discontinuation, varied significantly by study site, with use markedly higher in Los Angeles after adjusting for other factors. This difference in use may be driven by regional variation in both demand and supply side factors, such as the prevalence of direct-to-consumer advertising, community norms and preferences, and physician knowledge and attitudes. Interestingly, the regional variation was strongest among the HIV-infected men, possibly reflecting differing approaches to TTh within the HIV care setting. Other demographic factors were linked to TTh use; black men were less likely to use and more likely to discontinue TTh, compared with white men. Testosterone utilization was higher in the older age groups, although age was not independently associated after adjustment for co-factors, many of which are age-related conditions. TTh use was also positively correlated with having a high 10-year CVD risk, and TTh users in our cohort had a high prevalence of dyslipidaemia, hypertension and diabetes. Smoking was the sole CVD risk factor that was strongly inversely associated with TTh use; current smokers were much less likely to use TTh, and smokers who used TTh discontinued at twice the rate of nonsmokers. Among TTh users, discontinuation rates were fairly high; 20.9 per 100 person-years overall, and 29.2 per 100 person-years among HIV-uninfected men. Though the sample was small to investigate trends over time, the data suggest that the discontinuation rate may have increased in the period after the FDA safety communication, particularly among men in the moderate or high CVD risk groups. While we cannot determine the reasons for discontinuation, it is possible that media coverage about the potential risk of heart attack and stroke after the FDA communication [35] [36] [37] [38] influenced the behaviour of participants, 70% of whom were in the AHA/ACC high-risk category, and their prescribing physicians.
Limitations of our study include the self-reported ascertainment of TTh use; in particular, participants may have under-reported TTh use without a prescription. However, participants' self-reported reasons for TTh use revealed motivations that are valuable complements to the observed correlates of TTh use, and may help to explain differences in the durability of TTh use by HIV serostatus. Lacking data on TTh use before 2012, our study was not able to characterize duration of TTh use, or avoid the potential for reverse-causality and bi-directionality in the cross-sectional associations with TTh use. In contrast, we were able to assess the effect upon TTh usage of characteristics measured prior to the discontinuation, albeit for a short period of follow-up and without accounting for the duration of use prior to 2012. Ninety per cent of users self-reported a testosterone deficiency, but our study did not include data on serum testosterone level monitoring among men before or after TTh initiation, which several studies have documented to be suboptimal [1, 27, 39, 40] . The key strengths of our study are the standardized characterization of TTh use, including participant motivations for use; the large multi-city sample; and the prospective characterization of demographic, health and socio-behavioural factors for both HIVinfected and uninfected participants.
Our findings suggest that HIV-infected men, particularly those > 50 years old, constitute a significant group of TTh users. The present study has implications for practice and future research. HIV care providers should discuss the evidence on the potential benefits and risks of TTh with men currently taking TTh, to enable men to make informed choices regarding use. HIV-infected men choosing to continue or initiate TTh should be appropriately monitored and supported, including serum testosterone measurements per treatment guidelines. Men choosing to discontinue may benefit from therapeutic options to alleviate symptoms associated with discontinuation. These may include the short-term use of human chorionic gonadotropin or clomiphene citrate to facilitate the production of testosterone in men with secondary hypogonadism (neither are FDA-approved for this purpose), screening and treatment for anxiety or depression, anti-resorptive therapy for men with concomitant osteoporosis, and diet and physical activity programmes for body composition, energy and mood. In the research domain, our study found significantly lower rates of discontinuation among HIV-infected TTh users, and thus it would be useful for reports on trends in testosterone use and appropriate monitoring to report these data also in the subgroup with HIV infection, when data sources include HIV serostatus. In addition, more evidence is needed regarding the relative benefits and risks of longterm TTh use among men with HIV infection. The extent to which the current evidence on TTh, obtained primarily among men without HIV infection, is generalizable to HIV-infected men remains unclear. HIV-infected men are an important subgroup of testosterone users, and should be adequately represented in the research agenda addressing testosterone therapy, including participation in clinical trials. 
